Revolution Medicines Inc (RVMD) Stock Price, Quote & News

Company Profile

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 481 6801

Website: www.revmed.com

Address:

700 Saginaw Drive, Redwood City, United States

Jessypenny May. 17 at 7:33 AM

$DRTS $RVMD — RVMD just proved that showing real pancreatic cancer survival numbers moves a stock by billions. DRTS presents pancreatic data at ASCO in two weeks. RVMD beat chemo by doubling survival to 13.2 months. DRTS has 100% disease control in early pancreatic studies and hasn't even shown survival numbers yet (at ASCO?) . Same conference. Same cancer. Fraction of the market cap.

1 · Reply

Cm07458 May. 16 at 12:20 AM

$RVMD

0 · Reply

NEWBIGTECH May. 15 at 5:18 PM

$SLS $RVMD $RHHBY $ABBV

0 · Reply

justiceforb_85 May. 15 at 4:59 PM

$TNGX added. Look forward to vopimetostat data in combination with $RVMD.

0 · Reply

Macroghost May. 15 at 4:52 PM

If you look closely at comparables you’ll see $IBRX is the clear cut winner from both a risk standpoint and a return upside point of view. $IBRX vs $RVMD Market Cap, And Why SP500 Mega Cap Rotation Supercharges Biotech Small And Mid Caps!! https://youtu.be/9H37n-AE8nw

0 · Reply

Skoufc1 May. 15 at 4:33 PM

$RVMD bad market day for biotech

0 · Reply

55X_ROI_Q1_2026 May. 15 at 5:39 AM

$SLS $RVMD the IDMC UNBLINDED Phase 3 MOS AND IR DATA FROM THE ACTUAL INTERIM ANALYSIS. MOS and IR DATA that told all those paying attention, Gps is golden - including ABBV and BMY $RHHBY who own Aza Ven, the BAT for Control Patients. - look at the Share price / since the 60th Event was announced Dec 2024.Jan 2025: MCAP up from $77M to 1.29B - Share price up BIGLY - 160 Funds Invested up from 39 ... Look at the share Price since Dec 2025 when the 72nd Event was Announced. The 80th EVENT PR is going to launch this. for those who have no CLUE. BAT - Aza +VEN - Recently FAILED 3 Large Phase 3 Trials for AML Remission conducted by $ABBV. -- LASTLY - the 80th EVENT PR ... Is going to Launch this...

1 · Reply

Edu2050 May. 15 at 4:15 AM

$RVMD why on earth would someone invest in a co. That extends the pain nd suffering of a patient by 6 more months compared to chemo. Unbelievable. Wow.

2 · Reply

55X_ROI_Q1_2026 May. 15 at 12:47 AM

$SLS $RVMD for the INCH THIK MILE WIDE CREW: Gps is worth Tens of Billions. RNPV. Are you so ignorant you don't even know the IDMC UNBLINDED ACTUAL Phase 3 MOS AND IR DATA FROM THE ACTUAL INTERIM ANALYSIS. MOS and IR DATA that told all those paying attention, Gps is golden - including ABBV and BMY $RHHBY who own BAT for Control Patients. - look at the Share price / since the 60th Event was announced Dec 2024.Jan 2025: MCAP up from $77M to 1.29B - Share price up BIGLY - 160 Funds Invested up from 39 ... Look at the share Price since Dec 2025 when the 72nd Event was Announced. The 80th EVENT PR is going to launch this. for those who have no CLUE. BAT - Aza +VEN - Recently FAILED 3 Large Phase 3 Trials for AML Remission conducted by $ABBV. -- LASTLY - the 80th EVENT PR ... Is going to Launch this...

0 · Reply

55X_ROI_Q1_2026 May. 14 at 10:12 PM

$SLS Stock Twits #1 Trending Gps, an Immunotherapy to maintain Remission for all Acute Myeloid Leukemia final results are imminent* ™BALLISTIC VERTICALITY $RVMD REGAL Phase 3 Trial ongoing 5+ years, now rolling through the checkered flag. 49 patients remain 🙏 of 128 patients enrolled at Least 26 months ago ranging up to 64 months. Run4theRoses2 https://www.reddit.com/r/sellasLifescience/comments/1td6xjq/sls_free_money_anyone_investing_now_ahead_of_the/?utm_source=share&utm_medium=web3x&utm_name=web3xcss&utm_term=1&utm_content=share_button OP • SLS Announced the 60th Event, the share price Launched SLS Announced the 72 Event, the share price Launched SLS is about to announce the 80th and Final Event ... Not the results just the 80th event, the share Price will launch ahead of the Phase 3 Result, which is about 40x more valuable than the current share price. The 80th Event Puts a $40B Mountain in view. Upvote1DownvoteReply AwardShare Run4theRoses2 OP• - Ballistic Verticality incoming.

0 · Reply

US cancer clinics scramble to get experimental Revolution Medicines pancreatic cancer drug

2026-05-07T16:52:59.000Z - 10 days ago

Revolution Medicines price target raised to $185 from $170 at BofA

2026-05-07T16:42:48.000Z - 10 days ago

Revolution Medicines price target raised to $172 from $120 at Piper Sandler

2026-05-07T10:48:40.000Z - 10 days ago

Revolution Medicines price target raised to $205 from $175 at Guggenheim

2026-05-07T01:25:33.000Z - 10 days ago

Revolution Medicines reports Q1 EPS ($2.29), consensus ($1.84)

2026-05-07T01:23:10.000Z - 10 days ago

Revolution Medicines sees FY26 operating expenses of $1.7B-$1.8B

2026-05-07T00:22:46.000Z - 10 days ago

Revolution Medicines announces NEJM publication of data on Daraxonrasib

May 6, 2026, 6:00 PM EDT - 10 days ago

Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic Cancer

May 6, 2026, 5:01 PM EDT - 10 days ago

Promising Revolution Medicines pancreatic cancer drug has high rate of mostly manageable side effects

May 6, 2026, 4:30 PM EDT - 11 days ago

Revolution Medicines Earnings Call Transcript: Q1 2026

May 6, 2026, 4:02 PM EDT - 11 days ago

Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress

May 1, 2026, 12:54 PM EDT - 16 days ago

US FDA authorizes early access to Revolution's pancreatic cancer pill

2026-05-01T16:06:57.000Z - 16 days ago

FDA permits expanded access for Revolution pancreatic cancer drug

Apr 29, 2026, 4:05 PM EDT - 18 days ago

Revolution Medicines to Report Financial Results for First Quarter 2026 After Market Close on May 6, 2026

Apr 28, 2026, 5:30 AM EDT - 19 days ago

There's a Revolution in Cancer. But Can Big Pharma Afford It?

2026-04-27T14:37:58.000Z - 20 days ago

Erasca believes Revolution infringement claims ‘without merit,’ says Stifel

ERAS

2026-04-27T13:58:48.000Z - 20 days ago

Erasca sinks after Revolution Medicines alleges patent infringement

ERAS

Apr 21, 2026, 5:35 PM EDT - 25 days ago

Revolution Medicines to Present Updated Phase 1/2 Clinical Data for Daraxonrasib in First Line Metastatic Pancreatic Cancer Across Monotherapy and Combination Cohorts at the 2026 AACR Annual Meeting

Apr 21, 2026, 5:35 PM EDT - 25 days ago

Two experimental drugs showed striking early results against pancreatic cancer

BNTX

Apr 21, 2026, 5:30 PM EDT - 25 days ago

Revolution Medicines to Present Preclinical Data on Innovative Mutant-Targeted Catalytic RAS(ON) Inhibitor at the 2026 AACR Annual Meeting

Apr 21, 2026, 11:23 AM EDT - 26 days ago

Revolution Medicines to Present Pivotal Phase 3 RASolute 302 Clinical Trial Results for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer During a Plenary Session at the 2026 ASCO Annual Meeting

2026-04-19T20:25:47.000Z - 4 weeks ago

Revolution Medicines to present updated Phase 1 data for zoldonrasib

Apr 19, 2026, 2:00 PM EDT - 4 weeks ago

Revolution Medicines to Present Updated Phase 1 Clinical Data for Zoldonrasib in Patients with Previously Treated KRAS G12D Non-Small Cell Lung Cancer at the 2026 AACR Annual Meeting

Apr 17, 2026, 4:02 PM EDT - 4 weeks ago

Revolution Medicines Announces Closing of Concurrent Upsized Public Offerings with Aggregate Gross Proceeds of Approximately $2.2 Billion, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Apr 15, 2026, 12:10 PM EDT - 4 weeks ago

This Pill May Help Pancreatic Cancer Patients Live Longer

2026-04-15T09:50:40.000Z - 4 weeks ago

Revolution Medicines 10.563M share Secondary priced at $142.00

Apr 15, 2026, 12:41 AM EDT - 4 weeks ago

Revolution Medicines, Inc. Prices $2.0 Billion in Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes

2026-04-14T11:56:03.000Z - 4 weeks ago

Revolution Medicines price target raised to $200 from $140 at Evercore ISI

2026-04-14T11:51:09.000Z - 4 weeks ago

Revolution Medicines price target raised to $175 from $160 at Guggenheim

2026-04-14T11:25:01.000Z - 4 weeks ago

Revolution Medicines price target raised to $162 from $140 at RBC Capital

2026-04-14T10:10:12.000Z - 4 weeks ago

Revolution Medicines price target raised to $169 from $73 at H.C. Wainwright

2026-04-13T21:10:39.000Z - 4 weeks ago

Revolution Medicines files to sell $750M of common stock

2026-04-13T21:10:13.000Z - 4 weeks ago

Revolution Medicines files to sell $250M of convertible senior notes

Apr 13, 2026, 4:01 PM EDT - 4 weeks ago

Revolution Medicines, Inc. Announces Proposed Offerings of Common Stock and Convertible Senior Notes

Apr 13, 2026, 10:13 AM EDT - 4 weeks ago

Revolution Medicines surges 38% as pancreatic cancer drug shows breakthrough

Apr 13, 2026, 9:45 AM EDT - 4 weeks ago

Revolution Medicines' potential breakthrough pancreatic cancer drug succeeds in late-stage trial.

Apr 13, 2026, 9:11 AM EDT - 4 weeks ago

This Biotech Stock Soars 38%. Pancreatic Cancer Trial Was a Success.

Apr 13, 2026, 8:06 AM EDT - 4 weeks ago

Revolution Medicines' experimental cancer pill helps improve survival in late-stage study

Apr 13, 2026, 8:00 AM EDT - 4 weeks ago

Revolution Medicines' potential breakthrough pancreatic cancer drug succeeds in late-stage trial

Apr 10, 2026, 1:49 PM EDT - 5 weeks ago

Former Sen. Ben Sasse shines the spotlight on a possible breakthrough for pancreatic cancer

Mar 17, 2026, 6:37 PM EDT - 2 months ago

Revolution Medicines to Showcase Progress Across RAS(ON) Targeted Oncology Pipeline with Multiple Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting

Mar 3, 2026, 9:50 AM EST - 2 months ago

Revolution Medicines Transcript: TD Cowen 46th Annual Health Care Conference

Feb 25, 2026, 4:30 PM EST - 2 months ago

Revolution Medicines Earnings Call Transcript: Q4 2025

Feb 25, 2026, 4:02 PM EST - 2 months ago

Revolution Medicines Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress

Feb 24, 2026, 4:05 PM EST - 2 months ago

Revolution Medicines to Participate in TD Cowen 46th Annual Health Care Conference

Feb 18, 2026, 4:05 PM EST - 3 months ago

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2025 After Market Close on February 25, 2026

Feb 11, 2026, 9:30 AM EST - 3 months ago

Revolution Medicines Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 4, 2026, 4:05 PM EST - 3 months ago

Revolution Medicines to Participate in Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Jan 26, 2026, 4:30 PM EST - 3 months ago

Overlooked Stock: RVMD Sells After MRK Turns Away

MRK

Jan 25, 2026, 3:27 PM EST - 4 months ago

Merck no longer in talks to buy Revolution Medicines, WSJ reports

MRK

Jan 25, 2026, 2:30 PM EST - 4 months ago

Merck No Longer in Talks to Buy Revolution Medicines

MRK

Jan 12, 2026, 1:30 PM EST - 4 months ago

Revolution Medicines Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 9, 2026, 2:58 PM EST - 4 months ago

Merck is in talks to acquire Revolution Medicines in a deal that could value the cancer-drug biotech at around $30 billion

MRK

Jan 9, 2026, 5:54 AM EST - 4 months ago

Revolution Medicines Stock Soars. Takeover Buzz Grows, Another Suitor Emerges.

Jan 8, 2026, 3:56 PM EST - 4 months ago

Merck in talks to buy biotech Revolution Medicines, FT reports

MRK

Jan 8, 2026, 8:00 AM EST - 4 months ago

Revolution Medicines Announces FDA Breakthrough Therapy Designation for Zoldonrasib

Jan 8, 2026, 7:38 AM EST - 4 months ago

AbbVie Denies It's in Talks to Buy Revolution Medicines. Both Stocks Are Falling.

ABBV

Jan 7, 2026, 2:58 PM EST - 4 months ago

AbbVie in talks to buy biotech Revolution Medicines, WSJ reports

ABBV

Jan 7, 2026, 2:48 PM EST - 4 months ago

AbbVie Near Deal for Revolution Medicines

ABBV

Jan 5, 2026, 4:05 PM EST - 4 months ago

Revolution Medicines to Present at 44th Annual J.P. Morgan Healthcare Conference

Nov 18, 2025, 4:30 AM EST - 6 months ago

Revolution Medicines Transcript: Jefferies London Healthcare Conference 2025

Nov 11, 2025, 9:00 AM EST - 6 months ago

Revolution Medicines Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 5, 2025, 4:30 PM EST - 6 months ago

Revolution Medicines Earnings Call Transcript: Q3 2025

Nov 5, 2025, 4:02 PM EST - 6 months ago

Revolution Medicines Reports Third Quarter 2025 Financial Results and Update on Corporate Progress

Nov 4, 2025, 4:05 PM EST - 6 months ago

Revolution Medicines to Participate in November 2025 Investor Conferences

Oct 29, 2025, 4:05 PM EDT - 7 months ago

Revolution Medicines to Report Financial Results for Third Quarter 2025 After Market Close on November 5, 2025

Oct 27, 2025, 8:00 AM EDT - 7 months ago

Revolution Medicines' RAS(ON) Multi-Selective Inhibitor Daraxonrasib Granted U.S. FDA Orphan Drug Designation in Pancreatic Cancer

Oct 22, 2025, 12:12 PM EDT - 7 months ago

Revolution Medicines to Present Updated Elironrasib Safety and Efficacy Data in Patients with KRAS G12C Non-Small Cell Lung Cancer Following Treatment with a KRAS(OFF) G12C Inhibitor

Oct 16, 2025, 8:00 PM EDT - 7 months ago

Revolution Medicines Awarded Voucher for Daraxonrasib (RMC-6236) Under FDA Commissioner's National Priority Voucher Pilot Program

Sep 29, 2025, 9:00 AM EDT - 8 months ago

Revolution Medicines Announces Key Leadership Additions, including Alan Sandler, M.D. as Chief Development Officer

Sep 10, 2025, 5:00 PM EDT - 8 months ago

Revolution Medicines Transcript: Study Result

Sep 10, 2025, 4:02 PM EDT - 8 months ago

Revolution Medicines Shares New Clinical Results Supporting Initiation of RASolute 303, a Global Phase 3 Registrational Trial of Daraxonrasib in First Line Metastatic Pancreatic Ductal Adenocarcinoma

Aug 6, 2025, 4:30 PM EDT - 10 months ago

Revolution Medicines Earnings Call Transcript: Q2 2025

Aug 6, 2025, 4:02 PM EDT - 10 months ago

Revolution Medicines Reports Second Quarter 2025 Financial Results and Update on Corporate Progress

Jul 30, 2025, 4:05 PM EDT - 10 months ago

Revolution Medicines to Report Financial Results for Second Quarter 2025 After Market Close on August 6, 2025

Jul 24, 2025, 4:00 PM EDT - 10 months ago

Revolution Medicines Announces Publication of a Peer-Reviewed Research Paper in Science on the Discovery and Development of Zoldonrasib, a RAS(ON) G12D-Selective Inhibitor

Jul 23, 2025, 8:00 AM EDT - 10 months ago

Revolution Medicines Announces FDA Breakthrough Therapy Designation for Elironrasib

Jessypenny May. 17 at 7:33 AM

1 · Reply

Cm07458 May. 16 at 12:20 AM

$RVMD

0 · Reply

NEWBIGTECH May. 15 at 5:18 PM

$SLS $RVMD $RHHBY $ABBV

0 · Reply

justiceforb_85 May. 15 at 4:59 PM

$TNGX added. Look forward to vopimetostat data in combination with $RVMD.

0 · Reply

Macroghost May. 15 at 4:52 PM

0 · Reply

Skoufc1 May. 15 at 4:33 PM

$RVMD bad market day for biotech

0 · Reply

55X_ROI_Q1_2026 May. 15 at 5:39 AM

1 · Reply

Edu2050 May. 15 at 4:15 AM

$RVMD why on earth would someone invest in a co. That extends the pain nd suffering of a patient by 6 more months compared to chemo. Unbelievable. Wow.

2 · Reply

55X_ROI_Q1_2026 May. 15 at 12:47 AM

0 · Reply

55X_ROI_Q1_2026 May. 14 at 10:12 PM

0 · Reply

Quantumup May. 14 at 8:27 PM

Mizuho⬆️ $TNGX's PT to $30 and⬆️1L PDAC PoS to 75% while reiterating at an Outperform rating and saying: TNGX reported 1Q26 EPS and provided a pipeline update. $RVMD $IMRX ERAS BBOT Mizuho added—While all previously guided 2026 clinical updates (vopi-RAS(ON) combos, vopi in NSCLC and TNG456 in GBM) remain on track, TNGX noting that the registrational strategy for vopimetostat is under review (previously expected to start Phase III 2L PDAC trial). This decision was driven in part by the emerging RAS(ON) combo data, increased conviction in a path to 1L PDAC and a determination that capital allocation to this opportunity would be most impactful. We continue to believe vopi+RAS(ON) are positioned to demonstrate clinically meaningful additive benefit and are taking up our 1L PDAC POS (50%-->75%) on the basis of full RAS(ON) validation (via daraxonraib's RASolute 302). Reiterate Outperform with PT to $30 from $20, driven entirely by increased 1L PDAC risk-adjusted revenue assumptions.

1 · Reply

biolover May. 14 at 7:34 PM

$ERAS $RVMD $TNGX Does this group understand what they post 😂

2 · Reply

55X_ROI_Q1_2026 May. 14 at 4:50 PM

$SLS $RVMD FREE MONEY. Anyone INVESTING NOW ahead of the 80th EVENT is GUARANTEED Profit. The Share Price Will be climbing a $40B Mountain of Value - until it Absolutely Launches when we get the 80th Event PR. A SURE THING WINNER - massive Catalyst to Followed by Final Results Giving Gps the FDA Green Light to Generate Tens of Billions of Dollars - Tens of Billions in Real Revenue worth $40B to $LLY $ABBV - this $1.2B Manipulated Equity is worth $40B the Instant P3 Data Hits

0 · Reply

Ccg_ May. 14 at 4:44 PM

$RVMD 1) is another Sls paid poster posts, I’m buying puts until I go broke I don’t care. 2) today’s volume is very light. Makes me believe the mms sold their shares from delta hedging and are not expecting news today. Those rolls into June also make me think the “news” event now rolls into ASCO and June options

0 · Reply

55X_ROI_Q1_2026 May. 14 at 4:27 PM

$SLS The Price will certainly Launch with the 80th Event PR … a 100% Sure thing Guaranteed Win. $RVMD added $15B in market value in the 2 days after announcing their P3 Trial results. - something similar is about to happen here - Many Institutions will discover this next week. The Phase 3 Result will give Gps the FDA green light to treat 100,000 AML Patients Currently in Remission and another 40,000 or so Each Year. xCCO Estimated $300K Minimum Rev per patient Year 1. Infinite Dosing to Relapse - 2 -5 year Rev Per Patient. $28 B Total Addressable Market - worth Every Nickel of $40B to $LLY $ABBV $MRK ---

0 · Reply

55X_ROI_Q1_2026 May. 14 at 3:53 PM

$SLS We Will Be in Double Digits, at least $10 when the 80th Event is announced, and then the Share Price Launches. - 80th Event has Likely already Occurred - waiting for Data to Cycle through the PROCESS> $RVMD added $15B in Market Value the 48 hours after its P3 Results were announced. $ABVX was bumping around $5 , Stock doubled to $10 in the days ahead of its P3. T1 TRADING HALT on the ANNOUNCEMENT - and a + 600% GAP UP OPEN at $60 and it KEPT CLIMBING to a HIGH of $148 [+14.7B in Mcap] --- Based on P3 TRIAL DATA - SAME THING Similar will be Happening Here.

1 · Reply

55X_ROI_Q1_2026 May. 14 at 3:12 PM

$SLS $RVMD

0 · Reply

55X_ROI_Q1_2026 May. 14 at 2:53 PM

$SLS $RVMD going to be many hornè Funds buying Next week. $10 is cheap.

0 · Reply

SellasgpsCurativeBAT12 May. 14 at 2:25 PM

$RVMD $SLS $ABVX SLS mirroring exactly what happened at RVMD and ABVX before the big phase 3 positive data releases. RVMD MC over $32 Billion now. ✌️🙏

0 · Reply

55X_ROI_Q1_2026 May. 14 at 1:42 PM

$SLS $RVMD added $15B in market value in the 2 days after announcing their P3 Trial results. - something similar is about to happen here - Many Institutions will discover this next week $SLS The Price will certainly Launch with the 80th Event PR … a 100% Sure thing Guaranteed Win.

0 · Reply

hegdaom May. 14 at 1:18 PM

$IDYA $RVMD

0 · Reply

Cooper8119 May. 14 at 12:09 PM

$RVMD nytimes article

0 · Reply

Market Cap	30.97B
Revenue (ttm)	0.00
Net Income (ttm)	-1.13B
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.19

Volume	2,475,700
Avg Vol	3,010,340
Day's Range	N/A - N/A
Shares Out	212.60M
Stochastic %K	47%
Beta	1.41
Analysts	Strong Sell
Price Target	$181.30